MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
62.00
-1.57 (-2.47%)
Jul 24, 2026, 4:00 PM EDT - Market closed

MBX Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Income
-98.79-98.06-68.19-35.31-25.16
Net Income
-86.61-86.97-61.92-32.56-26.14
Earnings Per Share
-2.20-2.38-5.82-31.96-39.18
EPS Growth
-----

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
439.98373.71262.1580.6880.68
Total Debt
0.560.60.170.320.32
Net Cash (Debt)
439.42373.11261.9880.3580.35
Net Cash Growth
82.59%42.42%226.04%0%-
Net Cash Per Share
11.0510.2224.6278.87120.46

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-77.48-79.95-54.68-31.98-23.12
Capital Expenditures
-2.34-1.93-0.87-0.13-0.44
Free Cash Flow
-79.82-81.88-55.56-32.11-23.56
Free Cash Flow Growth
-----